CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 259 enrolled
Drug / intervention
Ergoferon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03039699
NCT03039699Phase 4Completed

International Multicenter, Double-blind, Randomized, Parallel Group Placebo-Controlled Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Viral Intestinal Infections in Children

Materia Medica Holding·interventional·Posted Feb 1, 2017·Updated Oct 19, 2020

In Brief

A Phase 4 clinical trial evaluating Ergoferon and Placebo for Viral Intestinal Infection. Completed, enrolled 259 participants across 13 sites in 2 countries.

Detailed Summary

The purpose of this study is to obtain additional data on efficacy and safety of Ergoferon in the treatment of viral intestinal infections in inpatient children.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesRussia, Uzbekistan
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 1, 2017
Enrollment StartJun 23, 2016
Primary CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.4 years ago

Interventions

Ergoferondrug

Placebodrug